Crinetics Pharmaceuticals CRNX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$496.39M-6.7% | -$465.32M-10.0% | -$423.1M-14.4% | -$369.83M-12.7% | -$328.25M-10.0% | ||
| $4.13M+6.0% | $3.89M+5.6% | $3.68M+7.0% | $3.44M+6.4% | $3.24M+16.2% | ||
| $100.23M+10.1% | $91.02M+3.3% | $88.15M+5.4% | $83.59M+9.4% | $76.41M+10.1% | ||
| -$51K-2.0% | -$50K— | —— | —— | —— | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | $17.96M+68.6% | $10.66M-20.0% | ||
| —— | —— | $26.34M+24.3% | $21.19M+61.7% | $13.1M+119% | ||
| —— | —— | —— | —— | -$305.5K-513% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$414.17M-9.6% | -$377.92M-7.4% | -$351.89M-15.8% | -$304M-14.4% | -$265.79M-15.5% | ||
| $5.34M-7.3% | $5.76M-9.0% | $6.33M+5.6% | $6M+59.9% | $3.75M-2.4% | ||
| $1.17B+16.3% | $1B-33.7% | $1.52B+6.1% | $1.43B-0.6% | $1.44B+25.4% | ||
| $1.18B-0.3% | $1.18B+8.0% | $1.1B+26.7% | $865.63M+10.9% | $780.9M+35.6% | ||
| $7.51M-95.7% | $173.91M+141% | -$425.29M+27.9% | -$590.1M+13.4% | -$681.69M-14.5% | ||
| $380.51M— | $0-100% | $32.1K-99.9% | $48.17M-87.9% | $398.17M-49.0% | ||
| $426.05M+949% | $40.61M-92.9% | $570.81M-8.7% | $625.05M-0.1% | $625.52M-38.4% | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | —— | ||
| $13.27M-14.0% | $15.43M-8.5% | $16.85M+0.5% | $16.77M+8.4% | $15.46M+3.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $26.34M+24.3% | $21.19M+61.7% | $13.1M+119% | ||
| —— | —— | —— | —— | —— | ||
| $1.18B-0.3% | $1.18B+8.0% | $1.1B+26.7% | $865.63M+10.9% | $780.9M+35.6% | ||
| —— | —— | —— | —— | $11.24M-25.0% | ||
| —— | $40.61M-2.4% | $41.61M-2.3% | $42.61M-2.3% | $43.61M-2.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | -$305.5K-513% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $4.8M— | —— | —— | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | —— | —— | $112K— | —— | ||
| -$419.52M-9.3% | -$383.68M-7.1% | -$358.23M-15.6% | -$310M-15.0% | -$269.54M-15.2% | ||
| -$419.52M-9.3% | -$383.68M-7.1% | -$358.23M-15.6% | -$310M-15.0% | -$269.54M-15.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Crinetics Pharmaceuticals generate?
- Crinetics Pharmaceuticals (CRNX) generated -$414.2M in operating cash flow over the trailing twelve months.
- What is Crinetics Pharmaceuticals's free cash flow?
- After $5.3M of capital expenditures, Crinetics Pharmaceuticals's free cash flow was -$419.5M over the trailing twelve months, down 55.6% year over year.
- Where does Crinetics Pharmaceuticals's cash flow data come from?
- Every line is extracted from Crinetics Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
